Market Place
Sourcing Support
Arch Biopartners` Cilastatin To Join PONTIAC Phase II Kidney Injury Trial
02 Aug 2024 //
GLOBENEWSWIRE
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin
27 Feb 2024 //
GLOBENEWSWIRE
Merck defends antibiotic`s approval from 2019
17 May 2023 //
ENDPTS
Enforcement Report - Week of February 22, 2023
22 Feb 2023 //
FDA
Merck is shutting the doors at a 300-person plant in PA
25 Mar 2022 //
FIERCEPHARMA
FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment
05 Jun 2020 //
MERCK
Results of Ph 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™
06 May 2020 //
BUSINESSWIRE
Results of Ph3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™
05 May 2020 //
BUSINESSWIRE
EMA’s Meeting highlights from CHMP) recommended five medicines for approval
14 Dec 2019 //
EMA
Merck touts Phase III data for antibacterial Recarbrio
30 Sep 2019 //
ENDPTS
Merck`s treatment for urinary, abdominal infections gets FDA approval
17 Jul 2019 //
REUTERS
Merck`s new combo med Recarbrio fights resistant bacteria
17 Jul 2019 //
FIERCE PHARMA
FDA Action Alert: Karyopharm, Merck and Celgene
01 Jul 2019 //
BIOSPACE
Merck scores a new Zerbaxa indication
05 Jun 2019 //
FIERCE PHARMA
FDA accepts two of MSD’s new drug applications
06 Feb 2019 //
PHARMA TIMES
Hospira Healthcare India Pvt. Ltd. on FDA Import Alert List
01 Aug 2018 //
FDA
Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI
12 Jan 2017 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.